Cannabis Law Report

JUNE 1, 2021

The initial shipment is designated to be used by the Clinic in a pilot run in preparation for the previously announced study , based out of the United Kingdom, on the safety and efficacy of cannabis and hemp for the treatment of patients suffering from chronic pain. Forward-Looking Statements.

Clinical Trials 89

Clinical Trials Chronic Pain Data Research and Development 89

Veriheal

MAY 30, 2023

But what if a safe and effective complementary plant-based treatment was widely available to alleviate cancer pain? of patients experience pain after curative treatment, while 66.4% in cancer patients undergoing anticancer treatment, 50.7% in those who had completed treatment, and as high as 66.7%

Medicine 96

Medicine Treatment Patients Data 96

Cannabis Law Report

JUNE 23, 2021

. “We are excited to be initiating our pilot program with Medicann in Jersey, which represents a unique, ‘ring-fenced’ environment for establishing potentially numerous studies on the efficacy of treatments using plant-based therapies. About RYAH Group, Inc. RYAH Group, Inc. Forward-Looking Statements.

Programs 100

Programs Data Events Collective 100

Cannabis Law Report

DECEMBER 7, 2021

Despite the increased use of medical cannabinoids, the efficacy and safety of the treatment among children remain uncertain. While cannabidiol was associated with a reduction in reported seizure events (RR?=?0.59, A qualitative assessment suggests that medical cannabinoids might be associated with adverse mental events.

Safety 52

Safety Cannabinoids Events Data 52

Cannabis Law Report

AUGUST 27, 2021

The Board will advise Delic and its subsidiaries, including Ketamine Infusion Centers, Delic Labs and others, as they develop safety protocols and best practices pertaining to legal psychedelic wellness treatments today and those legalized in the future. About Delic Corp, Inc.

Research and Development 98

Research and Development Treatment Media Medicine 98

Veriheal

JULY 12, 2021

According to the American Psychiatric Association , PTSD is a “psychiatric disorder that may occur in people who have experienced or witnessed a traumatic event such as natural disaster, as a serious accident, a terrorist act, war/combat or rape or who have been threatened with death, sexual violence or serious injury”.

Treatment 104

Treatment Sleep Clinical Trials Data 104

The Joint Blog

APRIL 17, 2020

This study summarizes potential adverse drug events related to THC when combined with other medications Medicinal Use of Marijuana Cannabis has been used widely across North America in various state or provincial medical marijuana programs. Diminishing efficacy of these receptors over time should be considered for proper treatment.

Events 48

Events THC Chronic Pain Sleep 48

Cannabis Law Report

JUNE 16, 2021

This engagement will build on the strong foundation on Santé, having treated more than 10,000 patients since 2014 under a real-world data protocol. Training will be provided within the research program for licensed practitioners to assess the safety of psychedelic medicines and to classify and report positive and adverse events.

Clinical Trials 104

Clinical Trials Therapy Research and Development Events 104

Cannabis Law Report

SEPTEMBER 15, 2021

This deceptive marketing of unproven treatments raises significant public health concerns because patients and other consumers may use them instead of approved therapies to treat serious and even fatal diseases. The FDA has received adverse event reports involving delta-8 THC-containing products. brownies, gummies).

THC 105

THC Pets Events Hemp 105

Cannabis Law Report

JULY 19, 2021

The data from the study is expected to be embedded into the RYAH MD platform, with the goal of enabling healthcare professionals to administer THC, CBD and terpenes in milliliters, which are then expected to automatically be converted into milligrams to allow for a customized, targeted patient inhalation session. “Our billion by 2027.

Therapy 76

Therapy Data Research and Development Events 76

Cannabis Law Report

AUGUST 17, 2021

(Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced topline data from its open-label Phase 2 trial evaluating safety and efficacy of adjunctive oral ganaxolone treatment in 23 patients with seizures associated with tuberous sclerosis complex (TSC).

Pharmaceutical 98

Pharmaceutical Clinical Trials Treatment Patients 98

Veriheal

JUNE 30, 2023

To start, participants reported that psilocybin had helped them process emotions tied to painful events in their past. Additionally, participants also reported feeling increased self-awareness and general improvement in relationships following their treatment. The Summit found that cannabis does not enhance athletic performance.

Clinical Trials 92

Clinical Trials Research and Development Therapy Policy 92

Cannabis Law Report

JULY 29, 2021

Tetra Bio-Pharma ( TSX: TBP ) ( OTCQB: TBPMF ) ( FRA:JAM1 ) is a leader in cannabinoid-derived drug discovery and development with a FDA and a Health Canada cleared clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. For more information visit: www.tetrabiopharma.com.

Research and Development 105

Research and Development Clinical Trials Events Cannabinoids 105

The Joint Blog

MARCH 3, 2021

The study is titled Medical cannabis for the treatment of fibromyalgia syndrome: A retrospective, open-label case series. in a cohort of 38 patients with treatment-resistant fibromyalgia. Thus, cannabinoids may be considered for FMS treatment, although several side effects may still occur. herbal cannabis, oil extracts, etc.)

Therapy 61

Therapy Hybrid Marijuana Research and Development 61

Cannabis Law Report

AUGUST 10, 2021

The global chronic pain treatment market is predicted to progress at a CAGR of 6.5% It is an honour and privilege to be in the position to use novel psychedelic treatments to solve the complex puzzle that is chronic pain. These statements relate to future events or future performance. billion in 2030. 3 Psychol Res Behav Manag.

Chronic Pain 105

Chronic Pain Clinical Trials Research and Development Events 105

The Joint Blog

JANUARY 3, 2020

Marijuana-based medicines “might be effective and safe in the treatment of tics and comorbidities” in those with Gilles de la Tourette Syndrome, according to a new study published in the journal Cannabis and Cannabinoids Research and e-published by the National Institute of Health. ” Dosages of all CBM varied markedly.

Data 49

Data Treatment Marijuana Patients 49

Cannabis Law Report

JULY 22, 2021

We believe that this will serve as a strong platform from which to deploy impactful alternative and psychedelic based treatment options,” stated Pouya Farmand, Chief Executive Officer of Levitee. About Levitee Labs. Levitee Labs is establishing itself as a leader in the integrative wellness space.

eCommerce 105

eCommerce Therapy Media Access 105

SpeedWeed

MARCH 13, 2021

However, common treatments do not address the non-motor symptoms and can sometimes cause side effects including dyskinesia, an abnormality or impairment of voluntary movement. . As a result, many patients turn to complementary or alternative treatments for their disease. . One such alternative treatment is cannabis.

Patients 52

Patients Treatment Therapy Sleep 52

The Cannigma

OCTOBER 21, 2021

Simon is not alone, one study reviewed online forum posts about cannabis and ADHD and found that 25% of posts indicated therapeutic benefits from this treatment – with statements like “While you are high … you will be able to focus much, much better than you normally would” and “(cannabis) helps me greatly with my ADHD.”

Blood Pressure 137

Blood Pressure Treatment Patients Cannabis 137

Veriheal

SEPTEMBER 15, 2021

This is very important if we wish to see a day where cannabis has been removed from harsh drug scheduling and if we wish to see it become part of everyday treatment practices by professionals. . Non-Experimental Research: Observational study, or non-experimental research, focuses on analyzing data in its natural context.

Data 81

Data Collective Environment Cannabis 81

Cannabis Law Report

AUGUST 12, 2021

Highlights: Phase IIb COMP360 psilocybin therapy trial for treatment-resistant depression (TRD) close to completion; on track to report data by end of 2021. On track to report top-line data by end of 2021. Net loss for the six months ended 30 June 2021 was $30.2 million, or $0.79 million) compared with $24.8 million, or $2.61

Clinical Trials 98

Clinical Trials Therapy Research and Development Data 98

The Blunt Truth

MARCH 10, 2020

CBD continues to flourish in the markets despite lack of federal regulations, and we’ve identified some significant events that indicate there’s no sign it’s stopping. Manufacturers are responsible for certifying records, including all product data, which includes, for example, information on formulation, labeling, and DEA Schedule.

CBD 99

CBD Topical Agriculture Food 99

Cannabis Law Report

OCTOBER 22, 2021

–The Company expects to hold a Research & Development event to review,these breakthrough findings in Q4 2021 that will be open to the public, shareholders, analysts and the media– TORONTO, CANADA – October 19, 2021 – Cybin Inc.

Research and Development 52

Research and Development Safety Media Data 52

Cannabis Law Report

JULY 28, 2021

Active research includes applications of machine learning and data mining as a member of the University of Alberta computational psychiatry group. His knowledge and insight will be paramount as we continue to navigate the development of DMT as a treatment for addiction disorders,” said Chief Executive Officer, Timothy Ko.

Research and Development 105

Research and Development Events Media Data 105

Cannabis Law Report

JANUARY 23, 2022

Events like these afford us a glimpse into the future of research and medicine in this field. At current, transplant treatments are hindered by our understanding of the immune response of those receiving treatments. The safety of CBD was noted even when administered in combination with the standard GVHD treatment.

Research and Development 52

Research and Development Wellness and Beauty Patients CBD 52

Cannabis Law Report

NOVEMBER 9, 2021

(“Delic” or the “Company”) (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) (Original Source), a leader in new medicines and treatments for a modern world, today announced the official, completed acquisition of Ketamine Wellness Centers Arizona LLC (“KWC”), becoming the largest chain of wellness centers providing ketamine treatments in the U.S.

Treatment 52

Treatment Therapy Media Access 52

Cannabis Law Report

SEPTEMBER 23, 2021

The major concerns noted were adverse events following consumption (many from inadvertent intoxication), marketing to and use by minors, and the potential presence of harmful by-products and unsafe manufacturing practices. The FDA has received adverse event reports involving delta-8 THC-containing products. CDC Health Alert.

THC 52

THC Concentrates Pets DEA 52

The Joint Blog

JANUARY 21, 2020

The study is titled Treatment of Gilles de la Tourette Syndrome in cannabis-based medicine: Results from a retrospective analysis and online survey. Materials and Methods: First, we performed a retrospective data analysis including all those adult patients seen at our clinic, who had used CBM for the treatment of GTS at some time.

Patients 29

Patients Marijuana Data Treatment 29

Cannabis Law Report

SEPTEMBER 20, 2021

KWC is a limited liability corporation formed under the laws of Arizona , which operates 10 ketamine infusion treatment clinics, across Arizona , Colorado , Florida , Illinois , Minnesota , Nevada , Texas , and Washington. Transaction Highlights.

Treatment 52

Treatment Media Research and Development Patients 52

Cannabis Law Report

JANUARY 13, 2020

Additional pipeline: Commence Phase 2b study of a cannabidiol formulation for the treatment of schizophrenia. Continue to explore CBDV in autism through a combination of open-label and investigator-led placebo controlled clinical trials with data from one or more of these programs in 2020. Commence clinical program in PTSD.

Pharmaceutical 66

Pharmaceutical Clinical Trials Research and Development Programs 66

Cannabis Law Report

JANUARY 12, 2022

As Oregon prepares to roll out the nation’s first legal psilocybin-assisted services program, there is a recognized need for the community to track adverse events and measure efficacy. Through the right mix of regulation, technology, and data, both are equally achievable,” says NPA CEO Britt Rollins.

Research and Development 52

Research and Development Therapy Safety Clinical Trials 52

Puff Puff Post

MARCH 10, 2020

.” Study 755-101-HV is a randomized, vehicle controlled, double-blind, Phase 1 trial, examining the safety and tolerability of two strengths of INM-755 cream in 22 healthy adult volunteers over a 14-day treatment period as part of a randomized, vehicle controlled, double-blind, Phase 1 trial.

Clinical Trials 84

Clinical Trials Pharmaceutical Research and Development Cannabinoids 84

Cannabis Law Report

OCTOBER 6, 2021

Flora Pharma will seek to identify scientific gaps in the cannabis industry and ultimately work to translate that to pharmaceutical cannabis products backed by data. The immediate next steps are to submit data for ethics committee review and approval whereupon acceptance, further details will be provided. “A

Clinical Trials 52

Clinical Trials Research and Development Pharmaceutical Events 52

Cannabis Law Report

DECEMBER 9, 2021

These describe technology and infrastructure for the collection of precise, multimodal, multivalent data that can be processed via machine learning, artificial intelligence, signal processes, and other statistical methods to yield clinically meaningful output to satisfy the requirements of the IFU.

Research and Development 52

Research and Development Clinical Trials Therapy Medicine 52

Illinois News Joint

APRIL 2, 2023

To find more cannabis-friendly events in Illinois, visit here. Below is Section 6z-112 of the State Finance Act that governs the distributions of the Cannabis Regulation Fund. For more Illinois cannabis industry news, visit here. For Illinois News Joint reviews, visit here. Expenditures for these purposes shall be subject to appropriations.

Education 85

Education Cannabis Collective Programs 85

Cannabis Law Report

FEBRUARY 2, 2022

“At Flora Growth, we believe in following the research, and there have been several promising studies published in just the last few months on the application of cannabinoids in certain treatments. About Flora Growth Corp. In addition, from time to time, we or our representatives may make forward-looking statements orally or in writing.

Cannabinoids 52

Cannabinoids Clinical Trials Events Cultivation 52

The Joint Blog

MARCH 18, 2021

According to a new study titled Use of cannabinoids for the treatment of patients with post-traumatic stress disorder, the consumption of cannabinoids and cannabinoid products is safe and effective in the mitigation of symptoms of post-traumatic stress (PTS). Researchers examined studies that used both natural and synthetic THC and CBD.

Cannabinoids 26

Cannabinoids Patients Clinical Trials Research and Development 26